Studies on objective indicator for predicting malignant potential of bladder cancer.

预测膀胱癌恶性潜能客观指标的研究

• 批准号: 04454409
• 负责人: TACHIBANA Masaaki
• 金额: $ 3.9万
• 依托单位: School of Medicine, Keio University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for General Scientific Research (B)
• 财政年份: 1992
• 资助国家: 日本
• 起止时间: 1992 至 1994
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-04454409/
• 关键词: Bladder cancer; Flow cytometry; DNA ploidy; Bromodeoxyuridine; Tumor invasiveness; Prognostic factor; 泌尿器科腫瘍; 浸潤性判定

In as much as urotherrial cancer consists of a spectrum of diseases with diverse natural histories, the conventional morphological classifications provided by classical histology still remain the hallmarks in the decisionmaking process. In the present study, an attempt was made to develope the objective and quantitative parameter for determination of malignant potential of bladder cancer. We have found that flow cytometric deoxyribonucleic acid(DNA)/bromodeoxyuridine bivariate analysis can provide important information on the malignant potential of bladder cancer. Also was found that the proliferative rate of the tumor cells in tumor may have significant importance since the rate of DNA synthesis is directly rerated to the rate of tumor growth or to tumor involvement. Then, we have formulated a new grading system based on the histological grade and tumor proliferative activity determinated by the BrdU labeling index. Each tumor was given a score ranging from 1 to 52. Fourty-four patients with a score of 1 demonstrated a 100% three-year survival rate, compared to 42.9% for patients having a score greater than 1. Conversely, 26 patients with the highest score of 52 presented a three-year survival rate of 17.3%. These results suggest that the new grading system can be used as an indicator in decision-making or treatment choice of transitional cell carcinoma of the bladder.

由于泌尿系癌症由一系列具有不同自然史的疾病组成，经典组织学提供的传统形态学分类仍然是决策过程中的标志。本研究试图建立一个客观、定量的膀胱癌恶性潜能判断指标。我们发现，流式细胞术脱氧核糖核酸（DNA）/溴脱氧尿苷双变量分析可以提供膀胱癌恶性潜能的重要信息。还发现肿瘤细胞的增殖速率可能具有重要意义，因为DNA合成速率直接与肿瘤生长速率或肿瘤浸润有关。然后，我们制定了一个新的分级系统的基础上，组织学分级和肿瘤增殖活性所确定的BrdU标记指数。每个肿瘤的评分范围为1至52。评分为1的44例患者的3年生存率为100%，而评分大于1的患者的3年生存率为42.9%。相反，26例最高评分为52分的患者的3年生存率为17.3%。结果表明，新的分级系统可作为膀胱移行细胞癌的决策或治疗选择的一个指标。

项目成果

Masaaki Tachibana: "A new scoring system bases on the histological behavior and proliferative activity of tumor cells for grading the malignant potential of bladder cancers" International Journal of Urology. 1. 37-42 (1994)

Masaaki Tachibana：“一种基于肿瘤细胞的组织学行为和增殖活性的新评分系统，用于对膀胱癌的恶性潜力进行分级”《国际泌尿学杂志》。

Ayako Miyakawa: "Flow cytometric measurements of deoxyribonuclic acid ploidy and proliferative activity for evaluating malignant potential of human bladder cancers" Cancer Detection and Prevention. 19(印刷中). (1995)

Ayako Miyakawa：“用于评估人类膀胱癌恶性潜能的脱氧核糖核酸倍性和增殖活性的流式细胞术测量”癌症检测和预防 19（出版中）。

宮川絢子、他: "Anchored cell analysis sorting(ACAS)system" Human Cell. 5. 392-397 (1992)

Ayako Miyakawa 等人：“锚定细胞分析分选 (ACAS) 系统”《人类细胞》5. 392-397 (1992)。

Tachibana, M., Miyakawa, A., Deguchi, N., Baba, S., Murai, M and Tazaki.H: "A new scoring system based on the histological behavior and proliferativeactivity of tumor cells for grading the malignant potential of bladder cancers" International Journal of U

Tachibana, M.、Miyakawa, A.、Deguchi, N.、Baba, S.、Murai, M 和 Tazaki.H：“一种基于肿瘤细胞的组织学行为和增殖活性的新评分系统，用于对膀胱恶性潜能进行分级

Miyakawa, A., Tachibana, M., Nakashima, J., Deguchi N., Baba, S.and Tazaki H: "Flow cytometric bromodeoxyuridine/deoxribonucleic acid bivariate analysis for predicting tumor invasiveness of upper tract urothelial cancer" The Journal of Urology. 152. 76-80

Miyakawa, A.、Tachibana, M.、Nakashima, J.、Deguchi N.、Baba, S.和 Tazaki H：“流式细胞术溴脱氧尿苷/脱氧核糖核酸双变量分析用于预测上尿路尿路上皮癌的肿瘤侵袭性”泌尿学杂志